P932: PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP

• Jay R. Hydren,
• Dee Lin,
• Jorge Arturo Hurtado,
• Nathan W. Sweeney,
• Bingcao Wu,
• Katharine Gries,
• Nina Kim,
• Saurabh Patel,
• Douglas W. Sborov,
• Jesus Berdeja,
• Larry D. Anderson,
• Jinhai Stephen Huo,
• Jennifer M. Ahlstrom

Affiliations

Jay R. Hydren

1 HealthTree Foundation, Lehi, UT

Dee Lin

2 Janssen Scientific Affairs, LLC, Horsham, PA

Jorge Arturo Hurtado

1 HealthTree Foundation, Lehi, UT

Nathan W. Sweeney

1 HealthTree Foundation, Lehi, UT

Bingcao Wu

2 Janssen Scientific Affairs, LLC, Horsham, PA

Katharine Gries

3 Janssen Global Services, LLC, Raritan, NJ

Nina Kim

2 Janssen Scientific Affairs, LLC, Horsham, PA

Saurabh Patel

4 Janssen US Oncology Medical Affairs, Horsham, PA

Douglas W. Sborov

5 Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT

Jesus Berdeja

6 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Larry D. Anderson

7 Myeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

Jinhai Stephen Huo

2 Janssen Scientific Affairs, LLC, Horsham, PA

Jennifer M. Ahlstrom

1 HealthTree Foundation, Lehi, UT